360 related articles for article (PubMed ID: 22872157)
1. Thrombopoietin-receptor agonists.
Basciano PA; Bussel JB
Curr Opin Hematol; 2012 Sep; 19(5):392-8. PubMed ID: 22872157
[TBL] [Abstract][Full Text] [Related]
2. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.
Zaja F; Barcellini W; Cantoni S; Carpenedo M; Caparrotti G; Carrai V; Di Renzo N; Santoro C; Di Nicola M; Veneri D; Simonetti F; Liberati AM; Ferla V; Paoloni F; Crea E; Volpetti S; Tuniz E; Fanin R
Am J Hematol; 2016 May; 91(5):E293-5. PubMed ID: 26910388
[TBL] [Abstract][Full Text] [Related]
3. New thrombopoietin receptor agonists for platelet disorders.
Homeida S; Ebdon C; Batty P; Jackson B; Kolade S; Bateman C; Peng YY; Stasi R
Drugs Today (Barc); 2012 Apr; 48(4):293-301. PubMed ID: 22536571
[TBL] [Abstract][Full Text] [Related]
4. Thrombopoietin-receptor agonists in haematological disorders: the Danish experience.
Gudbrandsdottir S; Frederiksen H; Hasselbalch H
Platelets; 2012; 23(6):423-9. PubMed ID: 22185370
[TBL] [Abstract][Full Text] [Related]
5. Thrombopoietin Receptor Agonists in Children with Immune Thrombocytopenia: A New Therapeutic Era.
Lassandro G; Palladino V; Vecchio GCD; Palmieri VV; Corallo PC; Faienza MF; Giordano P
Endocr Metab Immune Disord Drug Targets; 2021; 21(3):397-406. PubMed ID: 32473624
[TBL] [Abstract][Full Text] [Related]
6. Thrombopoietin receptor agonists in hereditary thrombocytopenias.
Rodeghiero F; Pecci A; Balduini CL
J Thromb Haemost; 2018 Sep; 16(9):1700-1710. PubMed ID: 29956472
[TBL] [Abstract][Full Text] [Related]
7. [Development of thrombopoietin receptor agonists].
Miyakawa Y
Rinsho Ketsueki; 2009 Oct; 50(10):1434-43. PubMed ID: 19915352
[No Abstract] [Full Text] [Related]
8. Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia.
Kuter DJ
Annu Rev Med; 2009; 60():193-206. PubMed ID: 19642221
[TBL] [Abstract][Full Text] [Related]
9. Sequential treatment with thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): experience in our center.
González KJ; Zuluaga SO; DaRos CV; Rodríguez PP; Martí AC
Ann Hematol; 2017 Mar; 96(3):507-508. PubMed ID: 27975127
[No Abstract] [Full Text] [Related]
10. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP).
Mazza P; Minoia C; Melpignano A; Polimeno G; Cascavilla N; Di Renzo N; Specchia G
Ann Hematol; 2016 Jan; 95(2):239-44. PubMed ID: 26596973
[TBL] [Abstract][Full Text] [Related]
11. Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study.
Neunert C; Despotovic J; Haley K; Lambert MP; Nottage K; Shimano K; Bennett C; Klaassen R; Stine K; Thompson A; Pastore Y; Brown T; Forbes PW; Grace RF;
Pediatr Blood Cancer; 2016 Aug; 63(8):1407-13. PubMed ID: 27135461
[TBL] [Abstract][Full Text] [Related]
12. Thrombopoietin receptor activation, thrombopoietin mimetic drugs, and hereditary thrombocytosis: remarks on bone marrow fibrosis.
Teofili L; Giona F; Martini M; Torti L; Cenci T; Foà R; Leone G; Larocca LM
J Clin Oncol; 2010 Jul; 28(19):e317-8. PubMed ID: 20516451
[No Abstract] [Full Text] [Related]
13. The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study.
Mahévas M; Fain O; Ebbo M; Roudot-Thoraval F; Limal N; Khellaf M; Schleinitz N; Bierling P; Languille L; Godeau B; Michel M
Br J Haematol; 2014 Jun; 165(6):865-9. PubMed ID: 24725224
[TBL] [Abstract][Full Text] [Related]
14. Thrombopoietin receptor agonists in patients with persistent or chronic immune thrombocytopenia.
Agnelli Giacchello J; Valeri F; Boccadoro M; Borchiellini A
Eur J Haematol; 2018 Mar; 100(3):304-307. PubMed ID: 29243329
[TBL] [Abstract][Full Text] [Related]
15. Thrombopoietin-receptor agonists for children with immune thrombocytopenia: a systematic review.
Zhang J; Liang Y; Ai Y; Xie J; Li Y; Zheng W
Expert Opin Pharmacother; 2017 Oct; 18(15):1543-1551. PubMed ID: 28845713
[TBL] [Abstract][Full Text] [Related]
16. Venous thromboembolism and coagulation activity in patients with immune thrombocytopenia treated with thrombopoietin receptor agonists.
Ghanima W; Lee SY; Barsam S; Miller A; Sandset PM; Bussel JB
Br J Haematol; 2012 Sep; 158(6):811-4. PubMed ID: 22816787
[No Abstract] [Full Text] [Related]
17. Thrombopoietin Receptor Agonist Use for Immune Thrombocytopaenia.
Neunert CE
Hamostaseologie; 2019 Aug; 39(3):272-278. PubMed ID: 30646404
[TBL] [Abstract][Full Text] [Related]
18. Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents.
Ghanima W; Junker P; Hasselbalch HC; Boiocchi L; Geyer JT; Feng X; Gudbrandsdottir S; Orazi A; Bussel JB
Br J Haematol; 2011 Oct; 155(2):248-55. PubMed ID: 21902682
[TBL] [Abstract][Full Text] [Related]
19. Thrombopoietin-receptor agonists for immune thrombocytopenia.
Jansen AJ; Swart RM; te Boekhorst PA
N Engl J Med; 2011 Dec; 365(23):2240-1. PubMed ID: 22150056
[No Abstract] [Full Text] [Related]
20. The new thrombopoietic agenda: impact on leukemias and MDS.
Bussel JB
Best Pract Res Clin Haematol; 2014; 27(3-4):288-92. PubMed ID: 25455280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
